Novo Nordisk shares plunged in early trading as the company pledged to launch more than five blockbuster drugs and deliver more than $23 billion in new sales in coming years. The plans disappointed investors hoping for more concrete turnaround plans from Chief Executive Officer Mike Doustdar after the Danish drugmaker lost its lead in the booming obesity market to Eli Lilly. Bloomberg's Sanne Wass reports. Video Transcript 00:00 Speaker A shares in Novo, Novo Nordisk, of course, falling and pretty sharply as you can see after announcing it aims to deliver more than 150 billion Danish Krona, that's about 23 billion dollars in pipeline sales in 2035. Novo is holding its capital markets day at a pivotal time for the drug maker.
Mostramos publicamente o ponto principal. Crie uma conta gratuita para continuar lendo o artigo completo, salva-lo, comenta-lo e conecta-lo ao contexto de mercado e OSINT.